Core Insights - Quantum BioPharma Ltd. is facing allegations of stock market manipulation, which is the focus of a three-part investigative series by CTV News' W5 [1][2] - The company has filed a USD $700 million lawsuit against CIBC and RBC, two of Canada's largest banks, related to these allegations [2] Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, including its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation associated with multiple sclerosis [4] - The company retains a 19.86% ownership stake in Unbuzzd Wellness Inc., which is involved in the development of a product called unbuzzd™, and has a royalty agreement that includes 7% of sales until total payments reach $250 million, after which the royalty rate drops to 3% [4] Legal Context - The investigative series highlights the illegal practice of "stock spoofing," which has reportedly harmed retail investors and is central to Quantum BioPharma's legal claims [2][3] - CEO Zeeshan Saeed emphasized the importance of addressing stock market manipulation to protect other companies and their stakeholders from similar experiences [3]